Abstract：
:In vivo approaches to liver gene therapy will require restriction of transgene expression to hepatocytes. Since targeting of viral vectors exclusively to the liver is not easy to achieve, use of liver-specific promoters for driving expression of therapeutic genes is an interesting alternative. We have shown previously that regulatory elements of the hepatotrophic hepatitis B virus (HBV) are strong and liver-specific in vitro and therefore might be useful in hepatic gene therapy. Here we describe recombinant adenoviruses in which the human LDL receptor gene is under the transcriptional control of the HBV core promoter, the core promoter linked directly to HBV enhancer I, or a HBV-CMV hybrid promoter, respectively. These viruses allowed for a moderate to strong expression of the LDL receptor gene in vitro in a hepatocyte-specific manner when compared with the CMV immediate-early promoter. In vivo experiments demonstrated that the promoter gave rise to an expression level comparable to that from the CMV promoter in mouse liver, but was very weak in lung and skeletal muscle. Thus, the HBV-CMV hybrid promoter is strong and hepatocyte specific both in vitro and in vivo even in the adenoviral context and would be a good choice for driving a therapeutic gene in liver gene therapy.
journal_name
Gene Therjournal_title
Gene therapyauthors
Sandig V,Löser P,Lieber A,Kay MA,Strauss Msubject
Has Abstractpub_date
1996-11-01 00:00:00pages
1002-9issue
11eissn
0969-7128issn
1476-5462journal_volume
3pub_type
杂志文章相关文献
GENE THERAPY文献大全abstract：:Defects of the mitochondrial genome cause a wide variety of clinical disorders. Except for rare cases where surgery or transplant is indicated, there is no effective treatment for patients. Genetic-based therapies are consequently being considered. On account of the difficulties associated with mitochondrial (mt) tran...
journal_title：Gene therapy
pub_type： 杂志文章,评审
doi：10.1038/gt.2008.91
更新日期：2008-07-01 00:00:00
abstract：:We have previously synthesized a new cationic liposome that displays high efficiency and low toxicity, 3 beta[l-ornithinamide-carbamoyl] cholesterol (O-Chol), using solid-phase synthesis. In this study, O-Chol was applied to in vitro and in vivo models of ovarian cancer. Intraperitoneal gene delivery for peritoneal di...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301704
更新日期：2002-07-01 00:00:00
abstract：:Gene therapy with viral vectors has progressed to clinical trials. However, the localization of viral vector delivery to diseased target sites remains a challenge. We tested the hypothesis that an adenoviral vector could be successfully delivered by complexation with a specific antibody that is bound to a biodegradabl...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301452
更新日期：2001-05-01 00:00:00
abstract：:Confinement of transgene expression to target cells is highly desirable in gene therapy. Current strategies of transcriptional targeting to tumors usually rely on tissue-specific promoters to control gene expression. However, such promoters generally have much lower activity than the constitutive viral promoters. We h...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3302029
更新日期：2003-08-01 00:00:00
abstract：:Development of efficient short-term gene transfer technologies for embryonic stem (ES) cells is urgently needed for various existing and new ES cell-based research strategies. In this study, we present a highly efficient, nonviral non-DNA technology for genetic loading of mouse ES cells based on electroporation of def...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3302342
更新日期：2004-11-01 00:00:00
abstract：:During the past decade, both in vitro and in vivo studies have provided new insights into the cellular and molecular mechanisms that govern angiogenesis and arteriogenesis. However, therapeutic angiogenesis clinical trials using recombinant protein or gene therapy formulations of single angiogenic growth factors have ...
journal_title：Gene therapy
pub_type： 杂志文章,评审
doi：10.1038/sj.gt.3302953
更新日期：2007-05-01 00:00:00
abstract：:HaCaT cells, a spontaneously immortalised, nontumorigenic keratinocyte line, were used as a more amenable model than primary keratinocytes for ex vivo-mediated gene transfer. These cells were transduced with retroviral vectors containing the factor IX cDNA under the control of a cytomegaloviral (CMV) promoter/enhancer...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3300591
更新日期：1998-03-01 00:00:00
abstract：:Radiosensitization of human gastrointestinal tumors by 5-fluorouracil (5-FU) has been studied in vitro and clinically in human cancer therapy trials. The bacterial enzyme cytosine deaminase (CD) converts the nontoxic prodrug 5-fluorocytosine (5-FC) into 5-FU. Human colon cancer cells stably expressing CD have been sho...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301196
更新日期：2000-06-01 00:00:00
abstract：:Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disease (LPD) after hematopoietic stem cell or solid organ transplantation remains a life-threatening complication. Expression of the virus-encoded gene product, EBER, has been shown to prevent apoptosis via blockade of PKR activation. As PKR is a major ce...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/gt.2012.93
更新日期：2013-07-01 00:00:00
abstract：:Recombinant adeno-associated virus type 2 (rAAV) vectors have recently been used to achieve long-term, high level transduction in vivo. Further development of rAAV vectors for clinical use requires significant technological improvements in large-scale vector production. In order to facilitate the production of rAAV ve...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3300937
更新日期：1999-06-01 00:00:00
abstract：:The role of two receptors, previously proposed to mediate the entry of adenoviruses into human cells, the coxsackie and adenovirus receptor (CAR) and the major histocompatibility complex (MHC) class I heavy chain has been investigated. The expression of MHC class I in many tumours is reduced or absent, therefore if th...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301006
更新日期：1999-09-01 00:00:00
abstract：:Both replication-incompetent and replication-selective adenoviruses are being developed for the treatment of cancer and other diseases. Concerns have been raised about the safety of intra-vascular adenovirus administration following a patient death on a clinical trial with a replication-defective adenovirus. In additi...
journal_title：Gene therapy
pub_type： 临床试验,杂志文章
doi：10.1038/sj.gt.3301512
更新日期：2001-11-01 00:00:00
abstract：:Adoptive cell therapy with chimeric antigen receptor (CAR)-modified T cells showed remarkable therapeutic efficacy in the treatment of leukaemia/lymphoma. However, the application to a variety of cancer entities is often constricted by the non-availability of a single chain antibody (scFv), which is usually the target...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/gt.2016.48
更新日期：2016-10-01 00:00:00
abstract：:Adenovirus-mediated gene therapy of experimental hepatocarcinoma is hindered by low transduction efficacy in vivo. We evaluated the extent of gene expression following various routes of administration of recombinant adenovirus AdCMVlacZ in diethylnitrosamine-induced rat hepatocarcinoma. We first characterized the vasc...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3300664
更新日期：1998-07-01 00:00:00
abstract：:Intramuscular (i.m.) injection of a plasmid encoding human carcinoembryonic antigen (CEA) elicited immunity against transplanted syngeneic (C57BL/6) CEA-positive Lewis lung carcinoma (CEA/LLC) cells, but tumors still appeared in all mice. In wild-type mice, coinjection of an IL-12 plasmid markedly enhanced anti-CEA hu...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301274
更新日期：2000-09-01 00:00:00
abstract：:Intramuscular (i.m.) injection of plasmids followed by electropermeabilization is an efficient process to deliver genes into skeletal myofibers that permits proteins to be produced and secreted at therapeutically relevant levels. To further improve skeletal muscle as a bioreactor, we identified a formulation that elev...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301806
更新日期：2002-10-01 00:00:00
abstract：:In the last two decades, remarkable advances have been made in the development of technologies used to engineer new aptamers and ribozymes. This has encouraged interest among researchers who seek to create new types of gene-control systems that can be made to respond specifically to small-molecule signals. Validation ...
journal_title：Gene therapy
pub_type： 杂志文章,评审
doi：10.1038/gt.2009.81
更新日期：2009-10-01 00:00:00
abstract：:The potential of gene therapy for treatment of lung disease remains unrealised. Early model systems often resulted in promising efficiency of gene transfer, only to prove irreproducible in the clinic. While problems such as induction of host immune responses and duration of expression also need to be addressed, it is ...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301146
更新日期：2000-04-01 00:00:00
abstract：:Somatic transgenesis can be used to confer endogenous production of proteins with therapeutic properties. One such product, recombinant soluble human CD4 (sCD4), has been shown to be an efficient inhibitor of human immunodeficiency virus 1 (HIV-1) in vitro, but its too short half-life in vivo has impaired long-term cl...
journal_title：Gene therapy
pub_type： 杂志文章
doi：
更新日期：1995-05-01 00:00:00
abstract：:Catheter-based percutaneous transluminal gene delivery (PTGD) into the coronary artery still falls behind the expectations of an efficient myocardial gene delivery system. In this study gene delivery was applied by selective pressure-regulated retroinfusion through the coronary veins to prolong adhesion of replication...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301079
更新日期：2000-02-01 00:00:00
abstract：:The sodium iodide symporter (NIS) mediates iodide uptake into thyrocytes and is the molecular basis of thyroid radioiodine therapy. We previously have shown that NIS gene transfer into the F98 rat gliomas facilitated tumor imaging and increased survival by radioiodine. In this study, we show that: (1) the therapeutic ...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3302147
更新日期：2004-01-01 00:00:00
abstract：:Gene modification of malignant cells to express immune stimulators (cytokines and immune costimulators) has provided the basis for a novel form of immunotherapy. Using a MPSV-based retroviral vector with hygromycin resistance gene as a selectable marker, we have studied retrovirus-mediated gene transfer of an immune c...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3300437
更新日期：1997-07-01 00:00:00
abstract：:We explored the possibility of using a genetic approach to inhibit integrin-mediated endothelial cell adhesion and survival. We constructed recombinant adenoviruses (Ads) expressing chimeric proteins consisting of the cytoplasmic and transmembrane domains of integrin beta1 (CH1), beta3 (CH3) or the beta1 transmembrane...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301236
更新日期：2000-08-01 00:00:00
abstract：:Gene delivery of angiogenic growth factors is a promising approach for the treatment of ischemic cardiovascular diseases. However, success of this new therapeutic principle is hindered by the lack of critical understanding as to how disease pathology affects the efficiency of gene delivery and/or the downstream signal...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3302781
更新日期：2006-09-01 00:00:00
abstract：:RNAi represents a powerful technology to specifically downregulate the expression of target genes. For cancer research and therapy, an efficient in vivo delivery system is supposed to distribute RNAi to all tumour cells upon systemic administration. We present replication-competent murine leukaemia virus (MLV) vectors...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/gt.2011.48
更新日期：2011-10-01 00:00:00
abstract：:By-pass surgery and percutaneous transluminal (coronary) angioplasty, PT(C)A, are standard techniques for the treatment of vascular occlusions. Their usefulness is limited by by-pass graft failure and restenosis occurring after the procedures. Twenty percent of patients treated with PTCA/PTA need a new revascularizati...
journal_title：Gene therapy
pub_type： 杂志文章,评审
doi：10.1038/sj.gt.3301866
更新日期：2002-11-01 00:00:00
abstract：:Apo(a) is a very atherogenic plasma protein without apparent function, which is highly expressed in humans. The variation in plasma Lp(a) concentration among individuals is considerable. Approximately 10-15% of the white population exhibit plasma Lp(a) concentrations above the atherogenic cut-off value of approximatel...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301434
更新日期：2001-03-01 00:00:00
abstract：:A retroviral vector constructed from the murine leukemia virus (MLV) can only express transgenes in cells undergoing mitosis, indicating its suitability as a delivery vehicle for cancer gene therapy. However, the transduction efficiency (TE) of retroviruses embedding endogenous envelope proteins in human cancer cells ...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3301390
更新日期：2001-02-01 00:00:00
abstract：:Intravenous delivery of adenoviruses is the optimal route for many gene therapy applications. Once in the blood, coagulation factor X (FX) binds to the adenovirus capsid and protects the virion from natural antibody and classical complement-mediated neutralisation in mice. However, to date, no studies have examined th...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/gt.2016.32
更新日期：2016-07-01 00:00:00
abstract：:An invasive Escherichia coli expressing the inv gene from Yersinia pseudotuberculosis was used as a vector for protein delivery to mammalian epithelial cells. Upon incubation with beta1-integrin-expressing mammalian cells, the bacteria are internalized, allowing bacteria-encoded proteins to function from within the ma...
journal_title：Gene therapy
pub_type： 杂志文章
doi：10.1038/sj.gt.3302281
更新日期：2004-08-01 00:00:00
